Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development
Back

Major Psychedelic Clinical Trial Data Is Right Around The Corner

Aug 19, 2021 • 7:12 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

During the last month, the psychedelic therapy sector has been under considerable pressure and we are closely following this volatile trend. 

Although momentum for the psychedelic therapy sector has been trending lower, we believe the industry has several significant potential growth catalysts. One of the most significant potential catalysts for growth is related to the publishing of data from advanced Food and Drug Administration (FDA) clinical trials from several high-profile biotech companies. 

There are a few companies that are working to develop breakthrough psychedelic treatments that are in Phase 2 and Phase 3 FDA clinical trials. In 2022, we expect several psychedelic therapy companies to publish data from these advanced clinical trials and believe that positive data will serve as a catalyst for the entire sector. 

FDA clinical trials are an expensive and extensive process and the strength of a company’s balance sheet is one of the first metrics that we analyze with a psychedelic therapy company. We prefer psychedelic biotech companies that own a defensible portfolio of intellectual property (IP) and that have the ability to tap the financial markets and raise capital as needed. If a company has been reporting positive FDA clinical trial data, we expect the capital raising process to be easier and consider these factors to be of key importance. 

Another data point that we consider to be significant and that we analyze for any psychedelic therapy company is the management team. We prefer operators that are led by a management team that has diverse expertise and a proven track record of success when it comes to advancing a treatment through FDA clinical trials and commercialization.

Shares of several leading Nasdaq traded biotech psychedelic therapy companies have fallen more than 50% from its 2021 highs and the last month has been especially challenging for the sector. We are of the opinion that the psychedelic therapy sector is in the early innings of a major growth cycle  and believe the sector is just getting starting to heat up.

If you are interested in learning more about leading psychedelic therapy companies, please send an email to support@mushroomstocks.com with the subject “Leading Psychedelic Therapy Companies” to be added to our distribution list.  

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link